Idiopathic thrombocytopenia purpura (ITP) is an acquired disease of children and adults characterized by a low platelet count, an essentially normal bone marrow, and absence of evidence for other disease. We report the use of syngeneic peripheral blood progenitor transplantation (PBPT) in a 19-year-old male with chronic refractory ITP since the age of 5. Engraftment was successful and has resulted in resolution of his disease. We conclude that syngeneic PBPT is a potentially curative option for refractory ITP.
Idiopathic thrombocytopenia purpura (ITP) is an acquired disease of children and adults characterized by a low platelet count, an essentially normal bone marrow, and absence of evidence for other disease. The clinical syndromes of ITP are distinct between children and adults: Childhood ITP characteristically is acute in onset and resolves spontaneously in most cases within 6 months, 1 whereas adult ITP typically has an insidious onset and rarely resolves spontaneously. [2] [3] [4] [5] The incidence of ITP in children is estimated to be approximately 46 new cases per million per year. Patients who fail to maintain a normal platelet count after conventional therapies are labeled as chronic refractory ITP patients. Treatment modalities include glucocorticoids, splenectomy, intravenous immunoglobulin (IVIG), anti-Rh (D) immune globulin, azathioprine, cyclophosphamide, vinca alkaloids, danazol, vitamin C, combination chemotherapy, cyclosporine, dapsone and interferon-␣-2b. [1] [2] [3] [4] [5] Recent information suggests that the anti-CD20 antibody, rituximab may be beneficial. 6 To date, limited information exists on the use of hematopoietic progenitor cell transplantation as a treatment for this disease. 
Case report

Past history
The patient, a 19-year-old male, was referred to the Tulane Bone Marrow Transplant program in January 2000 after a long history of chronic refractory ITP. He was diagnosed with ITP at the age of 5 in 1986. He was treated with steroids and had modest unsustained responses. Similarly, he had transient responses to intravenous immunoglobulin infusions (IVIG). The patient underwent a therapeutic splenectomy in February 1987, his ITP resolved and his platelet count normalized for a period of approximately 3 years. Recurrent ITP was precipitated by an infectious episode associated with fever, leukocytosis and thrombocytopenia. Subsequently, the patient developed chronic ITP with occasional spontaneous bruising but no bleeding episodes and a platelet count range of 10 to 50 000 ( Figure  1a) presentation to our center. During the 3 years preceding this referral platelet counts were frequently less than 10 000. During the past 10 years, the patient had multiple episodes of febrile illnesses of various etiologies that precipitated more severe thrombocytopenia and required repeated hospitalization and attempts at different treatment modalities for his ITP. His treatment prior to presentation to our center included IVIG, rhoGAM, steroids, cyclophosphamide and cyclosporine. Various dosages and combinations of the above listed medications were used with unsustained responses (Table 1) . He received corticosteroids in at least low doses for the majority of the preceding 10 years.
For the previous 2 years his thrombocytopenia had become very severe with a platelet count below 10 000 necessitating aggressive immunosuppressive treatments (Figure 1b) . This affected his functional status and resulted in several side-effects including infections, febrile illnesses, severe obesity and other long-term effects of prolonged term steroids. 
Stem cell transplant
The patient had a healthy male twin confirmed by molecular studies to be identical. In view of the debilitating nature of his disease and the low risk of GVHD, we proceeded to a syngeneic BMT in October 2000 when the patient was 20 years old. Pre-transplant investigations including cardiac ejection fraction, pulmonary function tests, renal and liver function were all normal. Conditioning consisted of a single fraction of total body irradiation (TBI) given at a dose of 5.5 Gy and cyclophosphamide at a dose of 50 mg/kg/day intravenous infusion over 1 h for 3 days. He also received Mesna prophylactically for hemorrhagic cystitis during the administration of cyclophosphamide. He then received a G-CSF-stimulated syngeneic peripheral blood progenitor cell transplant. The mononuclear cell dose was 10.3 ϫ 10 8 /kg containing a CD34 dose of 12.7 ϫ 10 6 /kg. In the post-transplant period, the patient developed myelosuppression, neutropenia, anorexia and gastrointestinal toxicity requiring total parenteral nutrition support. Recovery was complicated by a Staphylococcus line infection that responded to antibiotics. The patient successfully engrafted with a neutrophil count Ͼ0.5 ϫ 10 9 by day 8. He was discharged home on day 12 post transplant. In the post-transplant period, he required no red blood cell transfusions, however, he received a total of four platelet transfusions. His platelet count was 12 000 upon discharge. He had a low platelet count for 1 month that gradually increased to 98 000 on day 50 and reached a normal level of 148 000 on day 55. His platelet counts at 6 and 11 months (most recent) post transplant were 374 000 and 373 000, respectively. The patient is off all therapy and he is starting to regain a normal life.
Discussion
To our knowledge, this is the first case report of syngeneic PBPT for ITP. The transplant procedure was largely uncomplicated, and the patient is now disease free. The decision to proceed to transplant required careful consideration, since the risks associated with the transplant might well outweigh the consequences of ITP. There was little published experience on treatment of ITP with bone marrow transplant. Major review articles do not include bone marrow or PBPT as a treatment choice in ITP. [1] [2] [3] [4] Successful allogeneic BMT has been reported in cases of autoimmune diseases including immune hemolytic anemia, rheumatoid arthritis, psoriasis, SLE, ulcerative colitis and autoimmune hepatitis. 7 There has been a case report of successful resolution of immune thrombocytopenia and anemia in a patient with Evans syndrome who received an allogeneic cord blood transplant. 8 Unfortunately, that patient died of hepatic failure nine months post transplant. Use of autologous transplant for autoimmune diseases has also been reported. A recent summary of autologous PBPT in autoimmune disorders by Tyndall et al 9 included seven patients with ITP. No details of the cases were given, but overall, two were reported as better, two as stable, two worse, and one died of treatment-related complications. In a single case report, a patient with chemotherapy-induced autoimmune thrombocytopenia had recovery of normal platelet counts after autologous transplant. 10 Our patient had a low risk of complications by having Bone Marrow Transplantation an identical twin donor, a factor that markedly lowers the chance of GVHD. In addition, we also considered the morbidity and poor quality of life of this young man because of his disease. The post-transplant course was relatively unremarkable, minimal complications occurred and there was prompt recovery of granulocytes and red cells. No GVHD prophylaxis was given and no GVHD documented. Platelet recovery was somewhat delayed (55 days post transplant) but his platelet count normalized and remains in the normal range. In this case syngeneic PBPT appears to be a safe and effective treatment for chronic ITP. Syngeneic transplant for ITP should be considered when other modalities have failed after careful analysis of the risks and benefits of transplantation are compared to the risks of continued ITP and other therapies.
